NUP214 and B-cell acute lymphoblastic leukemia: Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic <i>NUP214</i>::<i>ABL1</i> Gene Fusion.